bioSyntagma
bioSyntagma gives clinicians and researchers a patient-specific view of cancer to inform therapy selection and limit acquired drug resistance. The company’s mPrint molecular fingerprint platform generates multi-omic, spatially resolved cell profiles and applies AI-driven analytics to recommend matched therapies and treatment strategies. The technology combines spatial transcriptomics, proteomics, and genomic profiling with machine learning to identify actionable biomarkers and treatment susceptibilities. The platform targets clinicians, academic researchers, and drug developers in the precision oncology market and supports clinical decision-making and therapeutic development.
bioSyntagma
bioSyntagma gives clinicians and researchers a patient-specific view of cancer to inform therapy selection and limit acquired drug resistance. The company’s mPrint molecular fingerprint platform generates multi-omic, spatially resolved cell profiles and applies AI-driven analytics to recommend matched therapies and treatment strategies. The technology combines spatial transcriptomics, proteomics, and genomic profiling with machine learning to identify actionable biomarkers and treatment susceptibilities. The platform targets clinicians, academic researchers, and drug developers in the precision oncology market and supports clinical decision-making and therapeutic development.